Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups.

ABSTRACT:

Background

Immunotherapy is now standard of care for multiple myeloma (MM), where the most common targets are B cell maturation antigen, CD38, and G protein-coupled receptor class C group 5 member D (GPRC5D). However, additional novel targets are needed to counter tumor heterogeneity, therefore new strategies to identify additional targets are also required.

Methods

We utilized multi-omics data from two large datasets A framework that utilized prior knowledge of cell surface potential, expression in healthy organs, and expression level in MM cells was established to define novel immunotherapeutic targets. High confidence targets were prioritized for myeloma populations and subgroups, validated with flow cytometry and immunoblotting.

Results

Novel population-level cand

SUBMITTER: Liu E 

PROVIDER: S-EPMC12261794 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature